Core Insights - WuXi AppTec has received validation from the Science Based Targets initiative (SBTi) for its near-term science-based emissions reduction targets, aligning with the goal of limiting global temperature rise to 1.5°C [1][2] - The company commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030 from 2024 levels and aims for a 25% reduction in absolute Scope 3 GHG emissions within the same timeframe [2] Sustainability Commitment - WuXi AppTec is implementing measures such as process optimization, equipment upgrades, and technological innovations to enhance energy efficiency and reduce carbon emissions [4] - The company is increasing its use of renewable energy through green electricity purchases and photovoltaic power generation facilities [4] - Collaboration with suppliers is a key strategy to reduce GHG emissions associated with purchased goods and services, promoting a low-carbon supply chain [4] Industry Recognition - WuXi AppTec has achieved an AA rating in MSCI ESG ratings for four consecutive years and has been included in the Dow Jones Sustainability Index (DJSI) for the same duration [5] - The company has received an A- Leadership rating in the CDP Climate Change rating for three consecutive years and has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics [5] Global Engagement - WuXi AppTec has joined the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner to further its sustainability commitment [6] Company Overview - WuXi AppTec operates globally, providing a broad portfolio of R&D and manufacturing services to the pharmaceutical and life sciences industry, enabling advancements in healthcare [7] - The company supports around 6,000 customers from over 30 countries, aiming to improve health outcomes and realize the vision that "every drug can be made and every disease can be treated" [7]

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. for alleged securities fraud affecting investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were negatively impacted by alleged fraudulent activities during the specified period [2]. - The complaint alleges that West Pharmaceutical Services made false statements regarding customer demand and concealed ongoing destocking issues in its high-margin HVP portfolio [3]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [3]. - The lawsuit also highlights that margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-term customers [3]. - As a result of these issues, the positive statements made by the defendants about the company's business and prospects were deemed materially false or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in complex securities litigation [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that affected investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding its customer demand visibility and attributed headwinds to temporary COVID-related product destocking, while in reality, it was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business, operations, and prospects were materially false and/or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses in West Pharmaceutical Services during the specified timeframe have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for aggrieved shareholders and has extensive expertise in complex securities litigation [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 7, 2025, to participate in potential recovery [4]. - Upon registration, shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock value [5].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud during the specified period [2]. Case Details - The complaint alleges that West Pharmaceutical Services made false statements and concealed significant issues, including: - The company was experiencing ongoing destocking in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - West Pharmaceutical Services (WST) shows potential for significant upside, with a mean price target of $284 indicating a 26.9% increase from the current price of $223.77 [1] Price Targets and Analyst Consensus - The average price target for WST ranges from a low of $245 to a high of $355, with a standard deviation of $34.94, indicating variability in analyst estimates [2] - The lowest estimate suggests a 9.5% increase, while the highest points to a 58.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about WST's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with one estimate moving higher and no negative revisions [12] - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as empirical research indicates that they often mislead investors [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

NEW YORK, June 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a mem ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased West common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements attributing issues to temporary COVID-related factors [5]. - The operational inefficiencies of the SmartDose device were said to be dilutive to profit margins, leading to potential restructuring activities and exit from key contracts [5].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand and attributed challenges to temporary COVID-related product destocking, while in reality, the company was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified time frame have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members, and there is no obligation to participate [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...